Winfried Alsdorf

Dr. Winfried Alsdorf is a Physician Scientist at the Second Medical Clinic and Polyclinic of the University Medical Center Hamburg-Eppendorf. With a prolific publication record spanning over a decade, his work focuses on advancing cancer treatments, particularly in hematologic malignancies and solid tumors. His research has significant clinical implications for patients with multiple myeloma, germ cell cancer, and prostate cancer.

Dr. Alsdorf's research interests center on novel immunotherapeutic approaches, with particular expertise in CAR-T cell therapy and bispecific antibodies for multiple myeloma treatment. His work also extends to germ cell cancer therapeutics, chemotherapy complications, and supportive care strategies. Recent publications demonstrate his leadership in investigating cutting-edge treatments including CLDN6-specific CAR-T cells, BCMA-targeted therapies, and PRAME-directed T cell approaches for solid tumors.

Analysis of Dr. Alsdorf's publication record reveals a strong trend toward immunotherapy research, particularly CAR-T cell applications across various cancer types. His work spans from basic science investigations of novel targets to large clinical trials and real-world implementation studies. Notably, he has contributed significantly to understanding the practical challenges of implementing advanced therapies like CAR-T cells in healthcare systems, as evidenced by his research on infrastructure requirements and financial burdens in Germany.

Dr. Alsdorf has established a robust collaborative network, frequently working with leading researchers including Prof. Bokemeyer and Prof. Weisel at the University Medical Center Hamburg-Eppendorf. His research program appears well-integrated within the university's oncology infrastructure, with connections to clinical trials units and translational research initiatives. While specific grant funding isn't detailed in the available information, his participation in numerous multicenter clinical trials suggests substantial research support.